English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  No consensus treatment has been reached for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Hepatic resection (HR) and transarterial chemoembolization (TACE) have been recommended as effective options, but which is better remains unclear. This meta-analysis is to compare the effectiveness of HR and TACE for HCC with PVTT patients.    Methods  The PubMed, EMBASE, Cochrane Library, VIP, Wan Fang, and Sino Med databases were systematically searched for comparing HR and TACE treating PVTT.    Results  Twelve retrospective studies with 3129 patients were included. A meta-analysis of 11 studies suggested that the 1-, 2-, 3-, and 5-year overall survival (OS) rates (OR = 0.48, 95% CI = 0.41–0.57, I 2  = 37%,  P  < 0.00001; OR = 0.21, 95% CI = 0.12–0.38, I 2  = 43%,  P  < 0.00001; OR = 0.35, 95% CI = 0.28–0.44, I 2  = 53%,  P  < 0.00001; OR = 0.28, 95% CI = 0.14–0.54, I 2  = 72%,  P  = 0.0001, respectively) favored HR over TACE. In a subgroup analysis, HR had better 1-, 2-,3, 5-year OS for type I PVTT (OR = 0.33, 95% CI = 0.17–0.64, I 2  = 20%,  P  = 0.001; OR = 0.32, 95% CI = 0.16–0.63, I2 = 0%,  P  = 0.001; OR = 0.18, 95% CI = 0.09–0.36, I2 = 0%,  P  < 0.00001; OR = 0.07, 95% CI = 0.01–0.32, I2 = 0%,  P  = 0.0006, respectively) and better 1-, 3-, and 5-year OS for type II PVTT (OR = 0.37, 95% CI = 0.20–0.70, I 2  = 59%,  P  = 0.002; OR = 0.22, 95% CI = 0.13–0.39, I 2  = 0%,  P  < 0.00001; OR = 0.16; 95% CI = 0.03–0.91; I 2  = 51%,  P  = 0.04, respectively). There was no difference in 1-, 3-, or 5-year OS between HR and TACE for type III PVTT (OR = 0.86, 95% CI = 0.61–1.21, I 2  = 0%,  P  = 0.39; OR = 0.83, 95% CI = 0.42–1.64, I 2  = 0%,  P  = 0.59; OR = 0.59, 95% CI = 0.06–-6.04, I 2  = 65%,  P  = 0.66, respectively).    Conclusions  HR may lead to longer OS for some selected HCC patients with PVTT than TACE, especially for type I or II PVTT, with less difference being observed for type III or IV PVTT.

bmc cancer

Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis